Bonesupport taps pharma veteran for CEO
This article was originally published in Clinica
Executive Summary
Bonesupport, a Swedish specialist in injectable bone substitutes and drug-eluting bone scaffolds, has appointed Richard Davies as CEO. Davies’ experience has mainly been with pharma companies, including Eli Lilly and Amgen, where he held various senior roles managing different geographic markets. Prior to joining Lund-based Bonesupport, he served as chief commercial offer at Hospira, before it was acquired by Pfizer last year. Davies replaces Lloyd Diamond, who will transition to the role of chief business officer. The latter will re-locate back to the US and help drive commercial growth of Bonesupport’s lead product, Cerament, in that market. In his four years as Bonesupport’s CEO, Diamond took the company past the R&D phase and into commercialization. The new CEO expects his pharmaceutical experience will help leverage the drug-eluting capabilities of Cerament.
You may also be interested in...
Bonesupport Brings In Former DePuy Exec As Head of North American Sales
Bonesupport has appointed a new general manager to oversee sales in North America as it steps up commercial efforts of its Cerament bone void filler platform.
Bonesupport Banks In More Cash, Pharma Expertise For Bioceramic Bone
Bone substitute materials specialist Bonesupport has strengthened its cash position with an influx of new capital, as well as installed a new chairman to strengthen its pharma know-how as it seeks to grow its drug-eluting bone scaffold business.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.